Carregant...
Miniatura

Tipus de document

Article

Versió

Versió publicada

Data de publicació

Llicència de publicació

cc by (c) Fernández Velasco, José I. et al, 2022
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/201067

Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology

Títol de la revista

Director/Tutor

ISSN de la revista

Títol del volum

Resum

To ascertain the role of inflammation in the response to ocrelizumab in primary-progressive multiple sclerosis (PPMS).Multicenter prospective study including 69 patients with PPMS who initiated ocrelizumab treatment, classified according to baseline presence [Gd+, n=16] or absence [Gd-, n=53] of gadolinium-enhancing lesions in brain MRI. Ten Gd+ (62.5%) and 41 Gd- patients (77.4%) showed non-evidence of disease activity (NEDA) defined as no disability progression or new MRI lesions after 1 year of treatment. Blood immune cell subsets were characterized by flow cytometry, serum immunoglobulins by nephelometry, and serum neurofilament light-chains (sNfL) by SIMOA. Statistical analyses were corrected with the Bonferroni formula.More than 60% of patients reached NEDA after a year of treatment, regardless of their baseline characteristics. In Gd+ patients, it associated with a low repopulation rate of inflammatory B cells accompanied by a reduction of sNfL values 6 months after their first ocrelizumab dose. Patients in Gd- group also had low B cell numbers and sNfL values 6 months after initiating treatment, independent of their treatment response. In these patients, NEDA status was associated with a tolerogenic remodeling of the T and innate immune cell compartments, and with a clear increase of serum IgA levels.Baseline inflammation influences which immunological pathways predominate in patients with PPMS. Inflammatory B cells played a pivotal role in the Gd+ group and inflammatory T and innate immune cells in Gd- patients. B cell depletion can modulate both mechanisms.Copyright © 2022 Fernández-Velasco, Monreal, Kuhle, Meca-Lallana, Meca-Lallana, Izquierdo, Oreja-Guevara, Gascón-Giménez, Sainz de la Maza, Walo-Delgado, Lapuente-Suanzes, Maceski, Rodríguez-Martín, Roldán, Villarrubia, Saiz, Blanco, Diaz-Pérez, Valero-López, Diaz-Diaz, Aladro, Brieva, Íñiguez, González-Suárez, Rodríguez de Antonio, García-Domínguez, Sabin, Llufriu, Masjuan, Costa-Frossard and Villar.

Citació

Citació

FERNÁNDEZ VELASCO, José i., MONREAL, Enric, KUHLE, Jens, MECA LALLANA, Virginia, MECA LALLANA, José e., IZQUIERDO, Guillermo, OREJA-GUEVARA, Celia, GASCÓN GIMENEZ, Francisco, SAINZ DE LA MAZA, Susana, WALO DELGADO, Paulette e., LAPUENTE SUANZES, Paloma, MACESKI, Aleksandra, RODRIGUEZ MARTÍN, Eulalia, ROLDÁN, Ernesto, VILLARRUBIA, Noelia, SAIZ HINAREJOS, Albert, BLANCO, Yolanda, DIAZ PÉREZ, Carolina, VALERO LÓPEZ, Gabriel, DÍAZ DÍAZ, Judit, ALADRO, Yolanda, BRIEVA, Luis, IÑÍGUEZ, Cristina, GONZÁLEZ SUÁREZ, Inés, RODRÍGUEZ DE ANTONIO, Luis a., GARCÍA DOMÍNGUEZ, José m., SABIN, Julia, LLUFRIU DURAN, Sara, MASJUAN, Jaime, COSTA FROSSARD, Lucienne, VILLAR, Luisa m.. Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology. _Frontiers In Immunology_. 2022. Vol. 13. [consulta: 24 de gener de 2026]. ISSN: 1664-3224. [Disponible a: https://hdl.handle.net/2445/201067]

Exportar metadades

JSON - METS

Compartir registre